Powerful new genomics method can be used to reveal the causes of rare genetic diseases

A team led by a scientist at Scripps Research has invented a new genomics technique for tracking down the causes of rare genetic diseases. The technique, which the researchers report in Science, makes use of the fact that people inherit two copies or "alleles" of virtually every gene, one from the mother and one from the father. The new method compares activity levels of maternal and paternal alleles across the genome and detects when the activity of an allele lies far enough outside the normal range to be a plausible cause of disease.

The researchers demonstrated their technique by using it to reveal disease-causing genes in patients with rare muscular dystrophies.

"Adding this method to our toolkit should allow us to detect the causes of rare genetic diseases for some of the cases in which standard methods fail," says study first author Pejman Mohammadi, PhD, an assistant professor in the Department of Integrative Structural and Computational Biology at Scripps Research.

Mohammadi began working on the project as a postdoctoral research associate in the Lappalainen lab at the New York Genome Center and Columbia University. After joining Scripps Research in 2018, he continued the research collaboratively with Lappalainen lab.

The team was focused on finding a better way to identify rare genetic diseases that emerge early in life and can be significantly debilitating or even life-threatening. Standard methods of sequencing genes and their transcripts - applied to the affected person and family members - usually can reveal the cause, but only if the disease-driving gene mutations are obvious ones that result in missing or severely truncated proteins.

At least half of rare genetic diseases have more subtle causes that effectively can't be detected using standard methods, Mohammadi says. For example, a mutation may affect a region of DNA that isn't itself a gene but is involved in regulating the activity of a gene--and the resulting dysregulation of that gene's activity can lead to disease.

The method developed by Mohammadi and his colleagues uses gene transcription data to detect differences in the activity levels of maternal and paternal alleles. Many rare genetic diseases result from DNA mutations affecting a single allele of a gene. Comparing the activity of maternal and paternal alleles, which share the same molecular environment in the same cells in the same person, is a more sensitive approach than comparing one person's gene activity to another's - since any two people will differ in many other confounding factors that affect gene activity besides their genetic backgrounds.

"Even if you had an identical twin, the fact that the twin ate a burger this morning and you didn't would create differences between you in the activity levels of many genes," Mohammadi says.

To help gauge when an allele's activity is truly abnormal, the method includes a calculation, from publicly available gene transcription data, of the normal, healthy range of differences in maternal versus paternal allele activity - for every gene.

The method, called ANEVA-DOT (analysis of expression variation - dosage outlier test), can be used to identify a handful of genes in each individual with apparently abnormal expression levels in one allele.

"It might tell you there are 10 or 20 genes with allele activity levels that are way off, and you can then follow up to determine which of those is causing the disease--but compared with other methods, it cuts down dramatically the number of genes you have to analyze in that way," Mohammadi says.

He and his colleagues demonstrated the ANEVA-DOT method by applying it to a group of patients with muscular dystrophy-type genetic diseases. They successfully detected the disease-linked genes in cases where there was already a diagnosis and an expected major imbalance in allele activity. In many of the undiagnosed cases, the ANEVA-DOT technique uncovered a short list of plausible disease-linked, muscle-related genes. In one case that was resolved by the time the researchers submitted their paper, a suspect gene uncovered by ANEVA-DOT was confirmed as the disease gene.

The scientists now are using ANEVA-DOT to help a San Diego children's hospital diagnose genetic disease in newborns.

Pejman Mohammadi, Stephane E Castel, Beryl B Cummings, Jonah Einson, Christina Sousa, Paul Hoffman, Sandra Donkervoort, Zhuoxun Jiang, Payam Mohassel, A Reghan Foley, Heather E Wheeler, Hae Kyung Im, Carsten G Bonnemann, Daniel G MacArthur, Tuuli Lappalainen.
Genetic regulatory variation in populations informs transcriptome analysis in rare disease.
Science, 10 Oct 2019. doi: 10.1126/science.aay0256

Most Popular Now

Roche's COVID-19 antibody test receives FDA Emerge…

Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that the U.S. Food and Drug Administration (FDA) has issued an Emergency Use Authorization (EUA) (1) for its new Elecsys® Ant...

Pfizer and BioNTech dose first participants in the…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced that the first participants have been dosed in the U.S. in the Phase 1/2 clinical trial for the BNT162 va...

Johnson & Johnson announces collaboration to e…

Johnson & Johnson (the Company) (NYSE: JNJ) announced a collaboration between the Janssen Pharmaceutical Companies of Johnson & Johnson and Emergent BioSolutions, Inc. to...

Early indicators of vaccine efficacy

Ludwig-Maximilians-Universität (LMU) in Munich researchers have shown that a specific class of immune cells in the blood induced by vaccination is an earlier indicator of...

Arthritis drug may improve respiratory function in…

A small study in Greece found that the clinically approved anti-inflammatory drug anakinra, used to treat rheumatoid arthritis, improved respiratory function in patients ...

Researchers urge clinical trial of blood pressure …

Researchers in the Ludwig Center at the Johns Hopkins Kimmel Cancer Center report they have identified a drug treatment that could - if given early enough - potentially r...

Frankfurt researchers discover potential targets f…

A team of biochemists and virologists at Goethe University and the Frankfurt University Hospital were able to observe how human cells change upon infection with SARS-CoV-...

Official COVID-19 deaths underestimate the full im…

According to a study by Charité - Universitätsmedizin Berlin, the northern Italian city of Nembro recorded more deaths during March 2020 than between January and December...

Local climate unlikely to drive the early COVID-19…

Local variations in climate are not likely to dominate the first wave of the COVID-19 pandemic, according to a Princeton University study published May 18 in the journal ...

Antibody neutralizes SARS and COVID-19 coronavirus…

An antibody first identified in a blood sample from a patient who recovered from Severe Acute Respiratory Syndrome in 2003 inhibits related coronaviruses, including the c...

Vitamin D linked to low virus death rate

A new study has found an association between low average levels of vitamin D and high numbers of COVID-19 cases and mortality rates across 20 European countries. The r...

AstraZeneca advances response to global COVID-19 c…

AstraZeneca is advancing its ongoing response to address the unprecedented challenges of COVID-19, collaborating with a number of countries and multilateral organisations...